Amsterdam, 24-25 Mai 2002: „Fifth FIAPAC-Conference“

  • 09:00-
    10:30
    Medikamentöser Abbruch -Neue Entwicklungen
    Chair:
    • Elisabeth Aubény, FR
    • Kristina Gemzell-Danielsson, SE
  • 10:30-
    11:00
  • 11:00-
    12:00
    Abbruch in Entwicklungsländern
    Chair:
    • Marijke Alblas, ZA
    Abbruch im zweiten Trimester
    Chair:
    • Thea Schipper, NL
    Medikamente während und nach einem medikamentösen Abbruch
    Chair:
    • Mirella Parachini, IT
    • close

      Medication After Medical Abortion -

      NSAIDs in pain treatment, Rh-immunoglobulin

       

      Christian Fiala

       

      Management of pain during medical abortion has been hampered by recommendations in the product information and guidelines from various sources that non-steroidal anti-inflammatory drugs (NSAIDS) should not be given to women at least until the follow-up visit eight to 12 days after mifepristone administration. Currently the summary of product characteristics for mifepristone includes advice that, ‘A decrease of the efficacy of the method can theoretically occur due to the antiprostaglandin properties of NSAIDS. Use preferably non-NSAI agents.’ The published evidence does not support these recommendations against the use of NSAIDs.

      Furtheromore NSAIDS are prostaglandin synthetase inhibitors and should have no adverse effect on exogenous prostaglandins. Stated alternatively, NSAIDs don't interfere with misoprostol and there are some good arguments for their use.

      The efficacy of medical abortion in Karolinska Institute and in the General Public Hospital in Korneuburg/Austria has been the same when NSAIDS are used

       

      Anti-D immune globulin is given in most places after early abortion, although evidence is lacking for the usefulness of this intervention at this early stage of pregnancy. Evidence-based guidelines for the administration of anti-D immune globulin (anti-D IgG) for women undergoing early spontaneous or induced abortions are missing. This is especially true for medical abortion, which is increasingly used in recent years.

      An ongoing study in Sweden is presented.

    Begleitung durch den Partner
    Chair:
    • Dominique Roynet, BE
  • 12:00-
    14:00
  • 14:00-
    15:30
    Verhütung und Sexualität nach einem Abbruch
    Chair:
    • Philippe Lefèbvre, FR
    • Mirella Parachini, IT
  • 15:30-
    16:00
  • 16:00-
    17:00
    Illegale Abbrüche?
    Chair:
    • Elisabeth Aubény, FR
    • Vicki Saporta, US
  • 17:00-